Mr. Dentzer is President, Chief Executive Officer and a member of the Board of Directors at Curis. Mr. Dentzer joined Curis in 2016 and was named CEO in 2018. Prior to joining Curis, Mr. Dentzer served as CFO of Dicerna Pharmaceuticals, where he led its IPO and successful follow-on financings. Earlier in his career, he held senior leadership positions with Amicus Therapeutics and Biogen. Mr. Dentzer earned a B.A. in Philosophy from Boston College and an M.B.A. from the University of Chicago. In 2021, Mr. Dentzer was named a Top 25 CEO in Biotech by The Healthcare Technology Report.